News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Press releases

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

2022

8 November, 2022
News
English
Regulatory
MAR
Report
Interim
Q3
IR
Optional
Interim report January-September 2022
25 October, 2022
News
Corporate Information
Nomination Committee
English
Regulatory
Listing Regulation
IR
Optional
Egetis presents Nomination Committee for the 2023 Annual General Meeting
19 August, 2022
News
English
Regulatory
MAR
VPML
Report
Interim
Q2
IR
Optional
Interim report Q2 2022
31 May, 2022
News
Corporate Action
Shares
English
Regulatory
LHFI
IR
Optional
Change in the number of shares and votes in Egetis Therapeutics
30 May, 2022
News
Corporate Information
General meeting
Report of the AGM
English
Regulatory
Listing Regulation
IR
Optional
Bulletin from Egetis Therapeutics’ Annual General Meeting 2022
19 May, 2022
News
Corporate Action
Shares
Issuance
English
Regulatory
MAR
IR
Optional
Egetis Therapeutics raises approximately SEK 180 million through an oversubscribed rights issue
28 April, 2022
News
Corporate Action
Prospectus
English
Regulatory
Listing Regulation
IR
Optional
Egetis Therapeutics publishes prospectus relating to the Rights Issue
26 April, 2022
News
English
Regulatory
MAR
Report
Interim
Q1
IR
Optional
Interim report January-March 2022
20 April, 2022
News
English
Regulatory
VPML
Report
Annual
IR
Optional
Egetis Therapeutics’ 2021 annual report published
13 April, 2022
News
Corporate Information
General meeting
Report of the AGM
English
Regulatory
Listing Regulation
IR
Optional
Bulletin from extraordinary shareholders’ meeting in Egetis Therapeutics AB and publication of timetable relating to the rights issue
21 March, 2022
News
Corporate Information
General meeting
Notice
English
Regulatory
Listing Regulation
IR
Optional
NOTICE OF EXTRAORDINARY GENERAL MEETING IN EGETIS THERAPEUTICS
21 March, 2022
News
Corporate Action
Shares
Issuance
English
Regulatory
MAR
IR
Optional
Egetis Therapeutics resolves on a fully guaranteed preferential rights issue of approximately SEK 180 million
17 February, 2022
News
English
Regulatory
MAR
Report
Interim
Yearend
IR
Optional
Significant progress towards Emcitate® marketing applications in the US and Europe in 2023
18 January, 2022
News
Corporate Information
Other Corporate Information
English
Regulatory
MAR
IR
mfn-cus-emcitate
Egetis concludes that demonstrating treatment effects on T3 levels in MCT8-deficiency could provide a basis for marketing approval for Emcitate® in the US

2021

13 December, 2021
News
Corporate Information
Other Corporate Information
English
Regulatory
MAR
IR
mfn-cus-emcitate
Egetis intends to submit a marketing authorisation application for Emcitate® to the European Medicines Agency based on existing clinical data
5 November, 2021
News
Corporate Information
Nomination Committee
English
Regulatory
Listing Regulation
IR
Nomination Committee appointed for the 2022 Annual General Meeting in Egetis Therapeutics
4 November, 2021
News
English
Regulatory
MAR
Report
Interim
Q3
IR
Interim report January-September 2021
19 August, 2021
News
English
Regulatory
MAR
VPML
Report
Interim
Q2
IR
mfn-cus-aladote
Emcitate development program progressing according to plan
24 May, 2021
News
Corporate Information
Other Corporate Information
English
Regulatory
Listing Regulation
IR
Chairman of the board of directors in Egetis Therapeutics acquires shares
17 May, 2021
News
Corporate Information
Other Corporate Information
English
Regulatory
Listing Regulation
IR
CEO and senior executives in Egetis Therapeutics acquire shares
29 April, 2021
News
Corporate Information
General meeting
Report of the AGM
English
Regulatory
Listing Regulation
IR
Bulletin from Egetis Therapeutics’ Annual General Meeting 2021
22 April, 2021
News
English
Regulatory
Listing Regulation
Report
Interim
Q1
IR
Patient recruitment in the pivotal study with Emcitate progressing according to plan
19 April, 2021
News
Corporate Information
Staff change
English
Regulatory
MAR
IR
Egetis Therapeutics appoints Yilmaz Mahshid as new CFO
30 March, 2021
News
English
Regulatory
VPML
Report
Annual
IR
Egetis Therapeutics 2020 annual report published
26 March, 2021
News
Corporate Information
Nomination Committee
English
Regulatory
Listing Regulation
IR
Mats Blom nominated as new board member at Egetis Therapeutics
Next

Calendar and upcoming reports

December 15, 2022
DNB Nordic Healthcare Conference

February 22, 2023
Year-end Report Q4 2022

Show more events

Share

Twitter
LinkedIn

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: info@egetis.com

Cookies
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept all”, you consent to the use of ALL the cookies. However, you may visit "Settings" to provide a controlled consent. Read our cookie policy
Settings Accept all
Cookies
Choose what kind of cookies to accept. Your choice will be saved for one year. Read our cookie policy
Save Accept all